www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products conditional agreement for High Density Aerosol use in Russia
Stirling Products (ASX: STI) and joint venture partner Zodiac Capital have entered into a conditional agreement with Cice Group for the exclusive use of the joint ventures Licensed High Density Aerosol (HDA).
The HDA would be used for the pulmonary delivery of a proprietary form of deltaran, which has been approved in Russia to treat brain damage, dementia and Alzheimer's disease.
The agreement is subject to due diligence for exclusivity for the Russian Federation and all former Soviet Union States, and following the establishment in this region, the exclusivity will be extended to incorporate all global rights.
The Licensee will be responsible for regulatory approvals for both the use of deltaran for pulmonary delivery and for the HDA delivery service.
The Licensee’s lead scientist and CEO, Dr Boris Voitenkov commented, “It is our intention to have approvals for the use of the HDA device for deltaran delivery in Russia within 12 months as the drug is already approved here and we can aim at achieving annual sales of around $100 million."


















